In a recent phase I/IIa study, patients with extensive-stage small cell lung cancer (SCLC) that had not previously been treated were given a drug called pomalidomide. The treatment was combined with standard chemotherapy consisting of cisplatin (Platinol) and etoposide (Etopophos/Toposar). Pomalidomide appeared to be safe, with a maximum tolerated dose of 4 mg/day. However, it did not appear to increase the efficacy or decrease the toxicity of the chemotherapy.